Infectious Disease Book

http://www.fpnotebook.com/

Respiratory Syncytial Virus Vaccine

Aka: Respiratory Syncytial Virus Vaccine, RSV Vaccine, Palivizumab, Synagis
Advertisement
  1. Mechanism
    1. Humanized mouse Monoclonal Antibody to RSV
  2. Indications: Based on AAP guidelines
    1. Chronic lung disease in age <2 years
      1. Medication treatment within 6 months of RSV season start
    2. Hemodynamically significant Congenital Heart Disease in age <2 years
    3. Consider in infants with severe Immunodeficiency
    4. Preterm Infants during their first RSV season
      1. Gestational age at birth <28 weeks (Give during first RSV season)
      2. Gestational age at birth 28-32 weeks who are under age 6 months during RSV season
      3. Gestational age 32-35 weeks with 2 risk factors:
        1. Child care attendance
        2. School-aged siblings
        3. Environmental pollution exposure
        4. Airway abnormality
        5. Severe neuromuscular disease
  3. Dosing
    1. Palivizumab 1 dose IM monthly for 5 months of RSV season (November 1 to March 1)
  4. Efficacy
    1. Decreases hospitalizations by 45 to 55%

Synagis (C0723567)

Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH C111186
English Synagis, palivizumab (Synagis), synagis, synagy, MedImmune brand of palivizumab, Abbott brand of palivizumab
Sources
Derived from the NIH UMLS (Unified Medical Language System)


palivizumab (C0672596)

Definition (NCI) A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. RSV F protein, a small envelop glycoprotein, is not only required for cytopathic syncytia resulting from cell-to-cell fusion, but is also necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibits fusion activity of RSV, thereby preventing syncytia formation. Administration of this antibody does not interfere with other immunizations.
Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH C111186
SnomedCT 108725001, 386900007
English palivizumab, palivizumab (medication), PALIVIZUMAB, palivizumab [Chemical/Ingredient], Palivizumab (product), Palivizumab (substance), Palivizumab, PALI
Spanish palivizumab (producto), palivizumab (sustancia), palivizumab
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Respiratory Syncytial Virus Vaccines (C0887894)

Definition (MSH) Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129)
MSH D022261
Swedish RSV-vacciner
Czech RSV vakcíny, viry respirační syncyciální - vakcíny
Finnish RSV-rokotteet
Russian VAKTSINY RESPIRATORNO-SINTSITIAL'NOVIRUSNYE, RESPIRATORNO-SINTSITIAL'NOVIRUSNYE VAKTSINY, ВАКЦИНЫ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОВИРУСНЫЕ, РЕСПИРАТОРНО-СИНЦИТИАЛЬНОВИРУСНЫЕ ВАКЦИНЫ
Japanese RSウイルスワクチン, 呼吸シンチウムウイルスワクチン, RSVワクチン, ワクチン-RSV, ワクチン-RSウイルス
English Respiratory Syncytial Virus Vaccines [Chemical/Ingredient], respiratory syncytial virus vaccines, rsv vaccine, RSV Vaccines, Respiratory Syncytial Virus Vaccines, Vaccines, RSV
Polish Szczepionki przeciw wirusowi RS, Szczepionki przeciw wirusowi syncytialnemu układu oddechowego, Szczepionki przeciw zakażeniu wirusem RS, Szczepionki RSV
French Vaccins anti-RSV, Vaccins anti-virus respiratoire syncytial, Vaccins contre RSV, Vaccins contre virus respiratoire syncytial
German Impfstoffe, RSV-, RSV-Impfstoffe, RSV-Vakzinen, Respiratory-Syncytial-Virus-Vakzinen
Italian Vaccini contro il virus respiratorio sinciziale
Portuguese Vacinas RSV, Vacinas contra Rsv, Vacinas contra Vírus Sincicial Respiratório
Spanish Vacunas VSR, Vacunas contra Virus Sincitial Respiratorio
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Navigation Tree